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Data were obtained via self-administered questionnaire and tele-
phone using trained interviewers. QOL domains used were those
identiﬁed by the OAB-q instrument developed by Coyne et al.
All proﬁle attributes had two levels: high/present and low/not
present. RESULTS: The linear ﬁxed-effects model resulted in the
following part-worth coefﬁcients for the ﬁve attributes of inter-
est: insurance coverage, 34.17; sleep, 23.55; concern, 19.59;
social, 19.28; coping, 15.61. Also reported is an analysis of
demographic variables with respect to symptom severity and
QOL. CONCLUSIONS: When deciding to treat OAB symptoms
with prescription medications, patients place the most impor-
tance on prescription drug insurance coverage. QOL domains
follow insurance in this order: sleep disturbances, symptom
concern, social disturbances, and coping.
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OBJECTIVES: To assess patient persistency in maintaining treat-
ment for Overactive Bladder (OAB). METHODS: Patients initi-
ating therapy on oxybutynin or tolterodine, immediate or
extended release, were tracked for 12-months, using a retail
pharmacy database. Five persistency classiﬁcation categories
were created to evaluate persistency as follows: on therapy, dis-
continued/no switch, discontinued/switched to one of the other
previously listed medications, reinitiated initial therapy, and off
therapy. Measurements included tracking the percent of patients
within each persistency classiﬁcation category, total therapy
days, and prescriptions dispensed for all medications. RESULTS:
The percentage of patients that discontinued their current
therapy and did not switch to another OAB therapy was 46.9%
at month three. By month four, more than half of all patients
were off therapy (55.4%). The percentage of patients off therapy
increased each month and reached 81.6% by the end of twelve
months. The percentage of patients that were switched to
another OAB medication did not exceed 3% in any month, nor
did the percentage of patients who reinitiated their initial therapy
surpass 3% in any month. The mean length of therapy was
approximately 86 days, with an average days supply of 30.
Approximately half of all patients were dispensed only one 
medication during the 12-month period. CONCLUSIONS:
Patient persistency with any currently marketed medications for
OAB remains poor, with less than 20% of study patients remain-
ing on therapy after 1 year.
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OBJECTIVES: The objectives of PURE are to understand the
direct cost of urinary incontinence (UI); describe the impact of
UI on health-related quality of life (HRQOL); and describe the
treatment patterns for women with UI in Europe in an outpa-
tient setting. METHODS: PURE is an ongoing, prospective,
observational study. More than 9000 patients will be recruited
in 13 European countries. The participating investigators are
primary care physicians and specialists (urologists, gynaecolo-
gists, geriatricians). The data will be prospectively collected at
baseline and at 2 points over a 6-month period. Assessments
include health care resource utilisation and treatments to derive
direct medical costs of UI care and describe the treatment pat-
terns, as well as symptoms and severity of UI and impact of UI
on patients’ lives. Baseline evaluation will additionally include
demographics, medical history, the assessment of HRQOL and
a retrospective data collection on health care resource utilisation
in the previous 12 months. RESULTS: By considering all the 10
priority research areas on the economics of UI identiﬁed by the
2nd international consultation on incontinence, PURE provides
a unique opportunity to assess the direct medical costs for UI
care in women across Europe. This will give insights to the eco-
nomic burden from the perspective of the national health care
systems, as well as from the patient, and will allow comparisons
of treatment patterns between countries in the light of different
health care systems and access to care. To our knowledge this is
the ﬁrst study undertaken in an outpatient setting to investigate
the economic and human impact of UI in Europe. CONCLU-
SIONS: PURE will address relevant clinical, economic and policy
research questions and will provide large-scale, comparative,
real-world information on the treatment and burden of UI across
Europe; data currently missing from the European literature but
needed to guide effective health policy.
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OBJECTIVES: Acute renal failure (ARF) is a prevalent and 
often preventable adverse drug event. Automated methods for
ARF identiﬁcation facilitate quality improvement and outcome
research, but traditional reliance on ICD9 codes has been shown
to underestimate the incidence. This study aimed to develop and
validate automated algorithms for the identiﬁcation of hospital-
acquired ARF. METHODS: A panel (nephrologist, internist,
clinical pharmacy specialist, pharmacoepidemiologist, database
analyst) deﬁned 3 algorithms based on existing literature and
available automated data: 1) 50% increase of serum creatinine
(SCr) within 3 days; 2) 50% SCr decrease between peak and 
discharge; and 3) ICD9 584.•• and charge code for dialysis. 
Each algorithm was linked (temporally and proximately) to 
drug exposure (aminoglycosides, amphotericin, cyclosporine,
tacrolimus, NSAIDs, or radiocontrast). Discharges with hospital
days <2 or ESRD (dialysis in ﬁrst 3 days of admission) were
excluded. Algorithms were applied to the laboratory and admin-
istrative databases of a large teaching hospital including dis-
charges between July 1, 2001 and June 30, 2002 (n = 20,639 or
10,536 with nephrotoxic drugs). Senior nephrology fellows to
verify the algorithms reviewed a random sample of positive
screened discharges. A random 20% of these were re-reviewed
